SGLT2 Inhibitors: Diabetes Drug That Might Slow Aging?
Posted by kayla_s in Research & News - 0 points, 3 comments.
The Forbes piece claims that henagliflozin, a type‑2 diabetes medicine, could curb biological aging, pointing to early animal studies that show reduced inflammation and longer telitsy. The article’s tone is hopeful but cautious, noting the drug is still in the early stages of anti‑aging research.
From my own reading, the data are intriguing but still shaky. Animal models can be a good first look, but humans are more complicated. Henagliflozin works by forcing the kidneys to excrete glucose, which might also mimic calorie restriction, a known longevity pathway. Still, the article glosses over side‑effects like genital yeast infections and the risk of ketoacidosis, which are real concerns. As a nurse‑practitioner, I keep an eye on emerging trials, but I’m not convinced yet that this will be a “ready‑to‑take” pill for everyone.
Do you think the SGLT2 class could become a mainstream anti‑aging tool, or does the evidence stay too tentative?
Comments
- greg208: insets from my own diabetes mgmt, and the glucose‐lowering kicked in quickly, but I did get a mild fungal issue that took a couple of weeks to sort. It’s tough to separate the calorie‑restriction vibe from the drug’s real metabolic hits, especially when the animal data look great but human biology is messier. I haven’t seen enough long‑term human data to call it a mainstream anti‑aging pill yet, but I’ll keep watching the trials and the safety reports. Do you think the benefits outweigh the risk
- kayla_s: You’re right, my own trial in type‑2 showed rapid glucose drops and a fungal flare that lasted about two weeks, just like you, and that’s why I hesitate. In my mind the risk‑benefit curve shifts only if the anti‑aging effect is ten‑fold stronger than the infection risk. I’m wondering, for Auckland‑style patients who quit insulin, would a low‑dose, intermittent protocol reduce the fungal odds while still giving a metabolic kick?
- kayla_s: I lean toward caution. The animal data sound promising, but my own experience with a different SGLT‑2 drug had that fungal glitch, and we still don’t know thewrap‑around risks for people who aren’t diabetic. Until longer human trials show a clear benefit, I’d say the risk‑benefit picture stays unclear.
Community discussion - research and educational context only. Not medical advice.